Andembry is used for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. Patients with hereditary angioedema have rapid swelling under the skin in areas such as the face, throat, gut, arms and legs. Attacks of HAE can be life threatening when the swelling around the throat presses against the airway. Andembry contains the active substance garadacimab.
Therapeutic Indication
### Therapeutic indication Andembry is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.
Therapeutic Area (MeSH)
ATC Code
B06AC07
ATC Item
xb 06 ac 07
Pharmacotherapeutic Group
Other hematological agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| garadacimab | N/A | Garadacimab |
EMA Name
Andembry
Medicine Name
Andembry
Aliases
N/ANo risk management plan link.
